Program
BI 1819479
A development code. Also written as “BI 1819479 (C-14)”.
Its studies are mostly in Idiopathic Pulmonary Fibrosis, led by Boehringer Ingelheim.
Furthest: phase 2, since Mar 22, 20246 company-led studies, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Boehringer Ingelheim | 60 open or running | phase 2since Mar 22, 2024 | Mar 15, 2021 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 15, 2021First study: phase 1 study in HealthyFirst studyNCT04801693 · 66 enrolled · Germany
- Jun 28, 2022Phase 1 study in HealthyNCT05440799 · 62 enrolled · Germany
- Jul 18, 20222 phase 1 studies in HealthyNCT05467475, NCT05469646
- Mar 22, 2024Phase 2 study in Idiopathic Pulmonary FibrosisNCT06335303 · 322 enrolled · United States, Argentina, Australia and more
- Jul 4, 2025Phase 1 study in HealthyNCT07065617 · 7 enrolled · United Kingdom
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07065617Healthy · United Kingdom | 1 | Terminated | Oct 4, 2025 | 7 |
| NCT06335303Idiopathic Pulmonary Fibrosis · United States, Argentina, Australia and more | 2 | Completed | Nov 25, 2025 | 322 |
| NCT05469646Healthy · Japan | 1 | Completed | Dec 20, 2022 | 24 |
| NCT05467475Healthy · Germany | 1 | Completed | Jan 23, 2023 | 15 |
| NCT05440799Healthy · Germany | 1 | Completed | Aug 2, 2023 | 62 |
| NCT04801693Healthy · Germany | 1 | Completed | Apr 25, 2022 | 66 |
How it is read
Names in the registry
- “BI 1819479”, 6 entries
- “BI 1819479 (C-14)”, 1 entry
Codes read as this program: BI1819479.
Conditions, from the studies’ own filings
- Idiopathic Pulmonary Fibrosis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.